Spanish scientists from the Banc de Sang i Teixits (BST) de Catalunya and the Institut d’Investigació Biomèdica de Bellvitge (Idibell) have signed an agreement to carry out research into the genetic modification of stem cells from umbilical cord blood.
Once again, stem cells obtained from umbilical cord blood are promising for the future of health, as well as being a fascinating field of research in medical science.
These cells, present in the umbilical cord blood of newborns, are remarkable for their capacity for self-renewal and their potential to differentiate into a variety of specialized cell types.
Their ability to form blood cells, such as red blood cells, white blood cells and platelets, is especially valuable for the treatment of various hematological diseases and genetic disorders.
Umbilical cord stem cells have proven to be a rich source of hematopoietic stem cells, which have been successfully used in bone marrow transplants to treat conditions such as leukemia and other blood cancers.
In addition, these cells possess unique immunomodulatory characteristics, which can contribute to the regeneration and repair of damaged tissues in various autoimmune diseases. An expert in this research explains: “We believe that our development will make it possible to produce immune system cells designed to attack specific therapeutic targets in a much faster, more effective and cheaper way than technologies currently being tested. Our system can also be applied to other diseases, such as fungal infections or those caused by antibiotic-resistant bacteria,” explained Daniel Bachiller, from the CIB. Read more about this news
Cell Therapy for Osteoporosis
October 27, 2021
